» Articles » PMID: 32244180

Metabolic Dysfunction in Polycystic Ovary Syndrome: Pathogenic Role of Androgen Excess and Potential Therapeutic Strategies

Overview
Journal Mol Metab
Specialty Cell Biology
Date 2020 Apr 4
PMID 32244180
Citations 164
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Polycystic ovary syndrome (PCOS) is the most common endocrinopathy among reproductive age women. Although its cardinal manifestations include hyperandrogenism, oligo/anovulation, and/or polycystic ovarian morphology, PCOS women often display also notable metabolic comorbidities. An array of pathogenic mechanisms have been implicated in the etiology of this heterogeneous endocrine disorder; hyperandrogenism at various developmental periods is proposed as a major driver of the metabolic and reproductive perturbations associated with PCOS. However, the current understanding of the pathophysiology of PCOS-associated metabolic disease is incomplete, and therapeutic strategies used to manage this syndrome's metabolic complications remain limited.

Scope Of Review: This study is a systematic review of the potential etiopathogenic mechanisms of metabolic dysfunction frequently associated with PCOS, with special emphasis on the metabolic impact of androgen excess on different metabolic tissues and the brain. We also briefly summarize the therapeutic approaches currently available to manage metabolic perturbations linked to PCOS, highlighting current weaknesses and future directions.

Major Conclusions: Androgen excess plays a prominent role in the development of metabolic disturbances associated with PCOS, with a discernible impact on key peripheral metabolic tissues, including the adipose, liver, pancreas, and muscle, and very prominently the brain, contributing to the constellation of metabolic complications of PCOS, from obesity to insulin resistance. However, the current understanding of the pathogenic roles of hyperandrogenism in metabolic dysfunction of PCOS and the underlying mechanisms remain largely incomplete. In addition, the development of more efficient, even personalized therapeutic strategies for the metabolic management of PCOS patients persists as an unmet need that will certainly benefit from a better comprehension of the molecular basis of this heterogeneous syndrome.

Citing Articles

Adropin ameliorates reproductive dysfunctions in letrozole-induced PCOS mouse.

Maurya S, Tripathi S, Arora T, Singh A Sci Rep. 2025; 15(1):8659.

PMID: 40082514 PMC: 11906834. DOI: 10.1038/s41598-025-93215-x.


Ultrasound Assessment in Polycystic Ovary Syndrome Diagnosis: From Origins to Future Perspectives-A Comprehensive Review.

Di Michele S, Fulghesu A, Pittui E, Cordella M, Sicilia G, Mandurino G Biomedicines. 2025; 13(2).

PMID: 40002866 PMC: 11853298. DOI: 10.3390/biomedicines13020453.


Ameliorative Effect of Combined Placenta-Derived Mesenchymal Stem Cells plus Platelet-rich Plasma on Polycystic Ovarian Model in Rats: A Biochemical and Histological Study.

Sarvestani M, Rajabzadeh A, Salimian M, Mazoochi T, Ghavipanjeh G Reprod Sci. 2025; 32(3):907-918.

PMID: 39856459 DOI: 10.1007/s43032-025-01791-0.


Polycystic ovary syndrome: Criteria, phenotypes, race and ethnicity.

Baba T Reprod Med Biol. 2025; 24(1):e12630.

PMID: 39845478 PMC: 11751892. DOI: 10.1002/rmb2.12630.


Association of TCF7L2 genetic variants rs12255372 and rs7903146 with the polycystic ovary syndrome risk: systemic review and meta-analysis.

Shah I, Rashid R, Rashid H, Bhat A, Ganie M J Ovarian Res. 2025; 18(1):2.

PMID: 39762965 PMC: 11702189. DOI: 10.1186/s13048-024-01585-z.


References
1.
Jensterle Sever M, Kocjan T, Pfeifer M, Kravos N, Janez A . Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin. Eur J Endocrinol. 2013; 170(3):451-9. PMC: 3922503. DOI: 10.1530/EJE-13-0797. View

2.
Holmang A, Svedberg J, Jennische E, Bjorntorp P . Effects of testosterone on muscle insulin sensitivity and morphology in female rats. Am J Physiol. 1990; 259(4 Pt 1):E555-60. DOI: 10.1152/ajpendo.1990.259.4.E555. View

3.
Jahromi M, Hill J, Ramezani Tehrani F, Zadeh-Vakili A . Hypomethylation of specific CpG sites in the promoter region of steroidogeneic genes (GATA6 and StAR) in prenatally androgenized rats. Life Sci. 2018; 207:105-109. DOI: 10.1016/j.lfs.2018.05.052. View

4.
Cernea M, Padmanabhan V, Goodman R, Coolen L, Lehman M . Prenatal Testosterone Treatment Leads to Changes in the Morphology of KNDy Neurons, Their Inputs, and Projections to GnRH Cells in Female Sheep. Endocrinology. 2015; 156(9):3277-91. PMC: 4541615. DOI: 10.1210/en.2014-1609. View

5.
Tuduri E, Lopez M, Dieguez C, Nadal A, Nogueiras R . Glucagon-Like Peptide 1 Analogs and their Effects on Pancreatic Islets. Trends Endocrinol Metab. 2016; 27(5):304-318. DOI: 10.1016/j.tem.2016.03.004. View